tiprankstipranks

Lyra Therapeutics downgraded to Market Perform from Outperform at William Blair

William Blair analyst Tim Lugo downgraded Lyra Therapeutics to Market Perform from Outperform after Lyra announced that the company’s Phase 3 ENLIGHTEN 1 trial evaluating LYR-210 for the treatment of chronic rhinosinusitis did not meet its primary endpoint.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue